Literature DB >> 17618409

[Fast and efficient healing of scleroderma-associated acral ulcers with sildenafil].

E Friedrichson1, P Rehberger, J T Fuhrmann, F Walz, M Meurer, C Pfeiffer.   

Abstract

Acral ulcers in patients with progressive systemic sclerosis (PSS) are often recalcitrant to therapy. Sildenafil, an inhibitor of phosphodiesterase-5, dilates small arteries by increasing endothelial cGMP. Oral administration of sildenafil to a 35-year-old white male patient suffering from incapacitating PSS with severe pulmonary arterial hypertension and acral ulcers induced a clinically significant reduction in dyspnea and increase in walking distance within one week as well as complete and long-lasting healing of all ulcers within five weeks. This case demonstrates the efficacy of sildenafil in the treatment of scleroderma-associated refractory acral ulcers.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 17618409     DOI: 10.1007/s00105-007-1366-1

Source DB:  PubMed          Journal:  Hautarzt        ISSN: 0017-8470            Impact factor:   1.198


  11 in total

Review 1.  [Natriuretic peptides BNP and NT-pro-BNP--the "new troponins" for estimation of heart failure?].

Authors:  R Pfister; E Erdmann; C A Schneider
Journal:  Dtsch Med Wochenschr       Date:  2003-05-02       Impact factor: 0.628

2.  Severe refractory fingertip ulcerations in a patient with scleroderma: successful treatment with sildenafil.

Authors:  Christopher Lee Colglazier; Paul G Sutej; Kenneth S O'Rourke
Journal:  J Rheumatol       Date:  2005-12       Impact factor: 4.666

Review 3.  [Raynaud phenomenon in dermatology : Part 2: therapy].

Authors:  C Sunderkötter; G Riemekasten
Journal:  Hautarzt       Date:  2006-10       Impact factor: 0.751

4.  Sildenafil citrate therapy for pulmonary arterial hypertension.

Authors:  Nazzareno Galiè; Hossein A Ghofrani; Adam Torbicki; Robyn J Barst; Lewis J Rubin; David Badesch; Thomas Fleming; Tamiza Parpia; Gary Burgess; Angelo Branzi; Friedrich Grimminger; Marcin Kurzyna; Gérald Simonneau
Journal:  N Engl J Med       Date:  2005-11-17       Impact factor: 91.245

5.  Sildenafil in the treatment of Raynaud's phenomenon resistant to vasodilatory therapy.

Authors:  Roland Fries; Kaveh Shariat; Hubertus von Wilmowsky; Michael Böhm
Journal:  Circulation       Date:  2005-11-08       Impact factor: 29.690

6.  Pulmonary hypertension in systemic sclerosis: an analysis of 17 patients.

Authors:  E T Koh; P Lee; D D Gladman; M Abu-Shakra
Journal:  Br J Rheumatol       Date:  1996-10

7.  [Treatment of therapy-resistant acral ulcers with iloprost].

Authors:  S von Schmiedeberg; S Artik; T Assmann; M Megahed; T Ruzicka
Journal:  Hautarzt       Date:  2004-12       Impact factor: 0.751

8.  Oral sildenafil as long-term adjunct therapy to inhaled iloprost in severe pulmonary arterial hypertension.

Authors:  Hossein A Ghofrani; Frank Rose; Ralph T Schermuly; Horst Olschewski; Ralph Wiedemann; André Kreckel; Norbert Weissmann; Stefanie Ghofrani; Beate Enke; Werner Seeger; Friedrich Grimminger
Journal:  J Am Coll Cardiol       Date:  2003-07-02       Impact factor: 24.094

9.  Primary pulmonary hypertension. A national prospective study.

Authors:  S Rich; D R Dantzker; S M Ayres; E H Bergofsky; B H Brundage; K M Detre; A P Fishman; R M Goldring; B M Groves; S K Koerner
Journal:  Ann Intern Med       Date:  1987-08       Impact factor: 25.391

10.  [Long-term effects of sildenafil in a patient with scleroderma-associated pulmonary hypertension and Raynaud's syndrome].

Authors:  S Rosenkranz; E Caglayan; F Diet; T Karasch; J Weihrauch; K Wassermann; E Erdmann
Journal:  Dtsch Med Wochenschr       Date:  2004-08-13       Impact factor: 0.628

View more
  4 in total

Review 1.  [Therapy of systemic sclerosis].

Authors:  M Meurer; P Rehberger
Journal:  Hautarzt       Date:  2007-10       Impact factor: 0.751

Review 2.  Advances in the treatment of Raynaud's phenomenon.

Authors:  Terri L Levien
Journal:  Vasc Health Risk Manag       Date:  2010-03-24

3.  Prospective, open-label, uncontrolled pilot study to study safety and efficacy of sildenafil in systemic sclerosis-related pulmonary artery hypertension and cutaneous vascular complications.

Authors:  Uma Kumar; Gokhale Sankalp; Sankalp S Gokhle; V Sreenivas; Satbir Kaur; Durgaprasanna Misra
Journal:  Rheumatol Int       Date:  2012-07-26       Impact factor: 2.631

4.  Effect of sildenafil on digital ulcers in systemic sclerosis: analysis from a single centre pilot study.

Authors:  Claudia S Brueckner; Mike O Becker; Thomas Kroencke; Doerte Huscher; Hans Ulrich Scherer; Margitta Worm; Gerd Burmester; Gabriela Riemekasten
Journal:  Ann Rheum Dis       Date:  2009-11-08       Impact factor: 19.103

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.